UK Regulator Says April Fee Rise Will Support 'Innovative & Efficient' Service
Executive Summary
The Medicines and Healthcare products Regulatory Agency says that the fee increases to be introduced on 1 April, along with 18 new fees, are necessary for its long-term financial sustainability and its ability to provide a “responsive, innovative and efficient regulatory service.”
You may also be interested in...
UK Regulator Plans New & Higher Fees To Ensure Financial Sustainability
The MHRA says pharmaceutical and medical device companies should be confident that planned changes to the fees structure will guarantee them “the high-quality service they expect.”
UK Regulator To Lose 20% Of Staff In Post-Brexit Cost-Cutting Plans
The MHRA intends to drop around 300 roles as it faces a financial crunch after leaving the EU and other pressures.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.